Interní Med. 2006; 8(12): 545-547

Atorvastatin: citius, altius, fortius?

MUDr. Jan Pi»ha
I. interní klinika FTN, IPVZ Praha

Atorvastatin belongs to the most important medications against cardiovascular diseases. The efficacy was proved on cardiovascular events and is mediated by its hypolipemic action. Its high doses (80 mg) were in the treatment of cardiovascular diseases safe and more effective than lower doses or medium doses of less potent statins. If the high dosage is more effective than medium doses of potent statins (40 mg atrovastatin and equivalent doses of other statins) is not clear. It is also not clear whether theses high doses are safe in combination with fibrates.

Keywords: Key words: atorvastatin, cardiovascular diseases, aggressiveness of treatment.

Published: March 1, 2007  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Pi»ha J. Atorvastatin: citius, altius, fortius? Interní Med. 2006;8(12):545-547.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Amarenco P, Bogousslavsky J, Callahan A 3rd, Goldstein LB, Hennerici M, Rudolph AE, Sillesen H, Simunovic L, Szarek M, Welch KM, Zivin JA; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006 10; 355 (6): 549-559. Go to original source... Go to PubMed...
    2. Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Motal SV, Hill KA, Pfeffer MA, Skene AN. Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction (TIMI) 22 Investigators. Intensive versus moderate lipid lowering with sttins after acute coronary syndromes. N Engl J Med 2004; 350: 495-504. Go to original source... Go to PubMed...
    3. Deedwania P, Barter P, Carmena R, Fruchart JC, Grundy SM, Haffner S, Kastelein JJ, LaRosa JC, Schachner H, Shepherd J, Waters DD; Treating to New Targets Investigators. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet. 2006; 368 (9539): 919-928. Go to original source... Go to PubMed...
    4. EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 1997; 18: 1569-1582. Erratum in: Eur Heart J 1998; 19: 356-357. Go to PubMed...
    5. EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur Heart J 2001; 22: 554-572. Go to original source... Go to PubMed...
    6. Grigioni F, Carigi S, Potena L, Fabbri F, Russo A, Musuraca AC, Coccolo F, Magnani G, Ortolani P, Leone O, Arpesella G, Magelli C, Branzi A. Long-term safety and effectiveness of statins for heart transplant recipients in routine clinical practice. Transplant Proc. 2006; 38 (5): 1507-1510. Go to original source... Go to PubMed...
    7. Jones PH, McKenney JM, Karalis DG, Downey J. Comparison of the efficacy and safety of atorvastatin initiated at different starting doses in patients with dyslipidemia.Am Heart J. 2005; 149 (1): e1. Go to original source... Go to PubMed...
    8. McCarey DW, McInnes IB, Madhok R, Hampson R, Scherbakov O, Ford I, Capell HA, Sattar N. Trial of Atorvastatin in Rheumatoid Arthritis (TARA): double-blind, randomised placebo-controlled trial. Lancet. 2004; 363 (9426): 2015-2021. Go to original source... Go to PubMed...
    9. Mohler ER 3rd, Hiatt WR, Creager MA. Cholesterol reduction with atorvastatin improves walking distance in patiens with peripheral arterial disease. Circulation. 2003; 108 (12): 1481-1486. Go to original source... Go to PubMed...
    10. Patel DN, Pagani FD, Koelling TM, Dyke DB, Baliga RR, Cody RJ, Lake KD, Aaronson KD. Safety and efficacy of atorvastatin in heart transplant recipients. J Heart Lung Transplant. 2002; 21 (2): 204-210. Go to original source... Go to PubMed...
    11. Pedersen TR, Faergeman O, Kastelein JJ, Olsson AG, Tikkanen MJ, Holme I, Larsen ML, Bendiksen FS, Lindahl C, Szarek M, Tsai J. Incremental decrease in end points through aggressive lipid lowering (ideal) study group. High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA. 2005; 294 (19): 2437-2445. Go to original source... Go to PubMed...
    12. Serebruany VL, Midei MG, Malinin AI, Oshrine BR, Lowry DR, Sane DC, Tanguay JF, Steinhubl SR, Berger PB, O'Connor CM, Hennekens CH. Absence of interaction between atorvastatin or other statins and clopidogrel: results from the interaction study. Arch Intern Med. 2004; 164 (18): 2051-2057. Go to original source... Go to PubMed...
    13. Widimský J, Vaněk P, Frantiąek J, Lánská V Stav kardiovaskulární farmakoterapie u nemocných po infarktu myokardu a/nebo revaskularizaci myokardu v roce 2005 v České republice. Vývoj za 5 a 10 let Cor Vasa 2006; 48 (4): 135-141.

    Return to the content


    Internal Medicine for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.